The role of dopamine for positive treatment expectations and placebo analgesia
- Conditions
- pain perceptionhealthy subjects
- Registration Number
- DRKS00029366
- Lead Sponsor
- Klinische Neurowissenschaften und translationale Schmerzforschung, Universitätsmedizin Essen, Klinik für Neurologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 169
Given informed consent to participation in the study
Exclusion criteria are the presence of any acute or chronic somatic or mental diseases, including several chronic pain conditions, abuse of illegal substances or alcohol, regular use of medication (except thyroid medication, allergy medication, occasional use of over-the-counter analgesics, and contraception); hypersensitivity, contraindications, allergy, or intolerance to any ingredients of the study medication; pregnancy or breastfeeding; and/or insufficient German language proficiency. Participants must not have taken part in studies using investigational drugs within the past three months and shall refrain from eating two hours prior to the experimental sessions.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Modulation of placebo analgesia on day 2. This is expressed as the interaction effect between experimental condition (placebo vs. control) and medication group (sulpiride vs. levodopa vs. control) on pain perception, which is assessed on a visual analogue scale from 0-100.
- Secondary Outcome Measures
Name Time Method